• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For February 2, 2024

    2/2/24 5:28:06 AM ET
    $ABBV
    $AON
    $BBU
    $BBUC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Insurers
    Finance
    Get the next $ABBV alert in real time by email

    Companies Reporting Before The Bell

    • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.

    • AbbVie (NYSE:ABBV) is likely to report quarterly earnings at $2.77 per share on revenue of $14.02 billion.

    • Cboe Global Markets (BATS:CBOE) is expected to report quarterly earnings at $2.03 per share on revenue of $511.68 million.

    • Charter Communications (NASDAQ:CHTR) is expected to report quarterly earnings at $8.68 per share on revenue of $13.70 billion.

    • Bristol-Myers Squibb (NYSE:BMY) is projected to report quarterly earnings at $1.53 per share on revenue of $11.19 billion.

    • Exxon Mobil (NYSE:XOM) is expected to report quarterly earnings at $2.21 per share on revenue of $85.23 billion.

    • Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to report quarterly earnings at $10.77 per share on revenue of $3.29 billion.

    • Chevron (NYSE:CVX) is projected to report quarterly earnings at $3.21 per share on revenue of $51.62 billion.

    • Cigna Group (NYSE:CI) is projected to report quarterly earnings at $6.53 per share on revenue of $48.89 billion.

    • Saia (NASDAQ:SAIA) is projected to report quarterly earnings at $3.20 per share on revenue of $744.99 million.

    • Twist Bioscience (NASDAQ:TWST) is expected to report quarterly loss at $0.78 per share on revenue of $67.58 million.

    • LyondellBasell Industries (NYSE:LYB) is expected to report quarterly earnings at $1.31 per share on revenue of $9.84 billion.

    • Capital Product Partners (NASDAQ:CPLP) is projected to report quarterly earnings at $0.63 per share on revenue of $95.71 million.

    • Brookfield Bus Partners (NYSE:BBU) is projected to report quarterly earnings at $6.42 per share on revenue of $16.55 billion.

    • IES Hldgs (NASDAQ:IESC) is projected to report earnings for its first quarter.

    • Banco Santander Chile (NYSE:BSAC) is projected to report quarterly earnings at $0.53 per share on revenue of $627.37 million.

    • Mizuho Financial Gr (NYSE:MFG) is expected to report earnings for its third quarter.

    • Virtus Inv (NYSE:VRTS) is projected to report quarterly earnings at $5.96 per share on revenue of $197.13 million.

    • Brookfield Renewable (NYSE:BEP) is projected to report quarterly loss at $0.04 per share on revenue of $1.07 billion.

    • Piper Sandler (NYSE:PIPR) is likely to report quarterly earnings at $2.60 per share on revenue of $370.12 million.

    • Brookfield Renewable (NYSE:BEPC) is expected to report quarterly loss at $0.14 per share on revenue of $1.21 billion.

    • Church & Dwight Co (NYSE:CHD) is likely to report quarterly earnings at $0.65 per share on revenue of $1.51 billion.

    • Johnson Outdoors (NASDAQ:JOUT) is likely to report quarterly earnings at $0.15 per share on revenue of $140.44 million.

    • WisdomTree (NYSE:WT) is expected to report quarterly earnings at $0.10 per share on revenue of $90.34 million.

    • Aon (NYSE:AON) is expected to report quarterly earnings at $4.06 per share on revenue of $3.36 billion.

    • Brookfield Business (NYSE:BBUC) is projected to report earnings for its fourth quarter.

     

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AON
    $BBU
    $BBUC

    CompanyDatePrice TargetRatingAnalyst
    Saia Inc.
    $SAIA
    2/11/2026$425.00Positive → Neutral
    Susquehanna
    Saia Inc.
    $SAIA
    2/10/2026$250.00Equal-Weight → Underweight
    Morgan Stanley
    Exxon Mobil Corporation
    $XOM
    2/3/2026$125.00Neutral → Underperform
    BNP Paribas Exane
    Exxon Mobil Corporation
    $XOM
    2/3/2026$135.00 → $145.00Buy
    TD Cowen
    Chevron Corporation
    $CVX
    2/2/2026$160.00 → $168.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    2/2/2026$180.00Buy → Hold
    HSBC Securities
    Church & Dwight Company Inc.
    $CHD
    2/2/2026$100.00Underweight → Neutral
    Analyst
    W.W. Grainger Inc.
    $GWW
    1/27/2026$1250.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ABBV
    $AON
    $BBU
    $BBUC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AON
    $BBU
    $BBUC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Epps Donna E bought $117,145 worth of shares (422 units at $277.60) and sold $117,075 worth of shares (422 units at $277.43) (SEC Form 4)

    4 - SAIA INC (0001177702) (Issuer)

    12/1/25 4:56:55 PM ET
    $SAIA
    Trucking Freight/Courier Services
    Industrials

    EVP, Global O&P and Refining Foley Kimberly A bought $246,621 worth of Class A Ordinary Shares (5,661 units at $43.56), increasing direct ownership by 9% to 67,688 units (SEC Form 4)

    4 - LyondellBasell Industries N.V. (0001489393) (Issuer)

    11/12/25 5:50:14 PM ET
    $LYB
    Major Chemicals
    Industrials

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    $ABBV
    $AON
    $BBU
    $BBUC
    SEC Filings

    View All

    SEC Form 13F-NT filed by Mizuho Financial Group Inc. Sponosred ADR (Japan)

    13F-NT - MIZUHO FINANCIAL GROUP INC (0001335730) (Filer)

    2/12/26 6:06:59 AM ET
    $MFG
    Major Banks
    Finance

    SEC Form 6-K filed by Banco Santander - Chile

    6-K - BANCO SANTANDER CHILE (0001027552) (Filer)

    2/11/26 3:29:25 PM ET
    $BSAC
    Commercial Banks
    Finance

    SEC Form 10-K filed by Bristol-Myers Squibb Company

    10-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    2/11/26 11:35:11 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AON
    $BBU
    $BBUC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fleming Susan S. sold $472,761 worth of shares (3,322 units at $142.31), decreasing direct ownership by 24% to 10,355 units (SEC Form 4)

    4 - VIRTUS INVESTMENT PARTNERS, INC. (0000883237) (Issuer)

    2/11/26 4:55:32 PM ET
    $VRTS
    Investment Managers
    Finance

    Chief Accounting Officer Werner Robert F. gifted 2,000 shares, decreasing direct ownership by 3% to 56,738 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/11/26 4:05:07 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP Controller Pitofsky Jason sold $1,585,058 worth of shares (2,036 units at $778.52) and exercised 1,000 shares at a strike of $492.00, decreasing direct ownership by 20% to 4,272 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/11/26 4:03:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AON
    $BBU
    $BBUC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Saia downgraded by Susquehanna with a new price target

    Susquehanna downgraded Saia from Positive to Neutral and set a new price target of $425.00

    2/11/26 7:50:53 AM ET
    $SAIA
    Trucking Freight/Courier Services
    Industrials

    Saia downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Saia from Equal-Weight to Underweight and set a new price target of $250.00

    2/10/26 2:29:18 PM ET
    $SAIA
    Trucking Freight/Courier Services
    Industrials

    Exxon Mobil downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Exxon Mobil from Neutral to Underperform and set a new price target of $125.00

    2/3/26 6:52:02 AM ET
    $XOM
    Integrated oil Companies
    Energy

    $ABBV
    $AON
    $BBU
    $BBUC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evernorth Health Services Teams Up with Direct Relief To Deliver Critical Medications to Communities Impacted by Disasters

    Evernorth's home delivery pharmacy donated more than 41,000 prescription medications to Direct Relief for initial supply Collaboration creates a scalable, replicable model for pharmacies to support disaster preparedness and future humanitarian responseBLOOMFIELD, Conn., Feb. 12, 2026 /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI), has partnered with Direct Relief to donate more than 41,000 lifesaving prescription medications for rapid deployment during natural disasters and other emergencies. Through this collaboration, Evernorth's Express Scripts Pharmacy has created a first–of–its–kind donation pathway that enables humanitarian organizations to source

    2/12/26 9:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Aon Appoints Joe Peiser as CEO of Risk Capital

    DUBLIN, Feb. 12, 2026 /PRNewswire/ -- Aon plc (NYSE:AON), a leading global professional services firm, today announced the appointment of Joe Peiser as CEO of Risk Capital.  In this role, Peiser will lead Aon's Risk Capital capabilities across Commercial Risk and Reinsurance Solutions. Peiser will continue to report to Andy Marcell, CEO of Global Solutions for Aon. A search for the role of CEO of Commercial Risk is underway. Peiser's appointment reflects Aon's broader strategy to strengthen how the firm helps clients navigate increasing volatility by connecting risk with the most efficient forms of capital. Peiser's enhanced leadership role will accelerate Aon's work to deliver solutions tha

    2/12/26 8:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    $AON
    $BBU
    $BBUC
    Leadership Updates

    Live Leadership Updates

    View All

    Aon Appoints Joe Peiser as CEO of Risk Capital

    DUBLIN, Feb. 12, 2026 /PRNewswire/ -- Aon plc (NYSE:AON), a leading global professional services firm, today announced the appointment of Joe Peiser as CEO of Risk Capital.  In this role, Peiser will lead Aon's Risk Capital capabilities across Commercial Risk and Reinsurance Solutions. Peiser will continue to report to Andy Marcell, CEO of Global Solutions for Aon. A search for the role of CEO of Commercial Risk is underway. Peiser's appointment reflects Aon's broader strategy to strengthen how the firm helps clients navigate increasing volatility by connecting risk with the most efficient forms of capital. Peiser's enhanced leadership role will accelerate Aon's work to deliver solutions tha

    2/12/26 8:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    Piper Sandler Strengthens Energy & Power Investment Banking with the Addition of Tim Carlson

    Piper Sandler Companies (NYSE:PIPR), a leading investment bank, is pleased to announce the addition of Tim Carlson as a managing director on the energy & power investment banking team. Carlson will focus on upstream. "Tim is another strong example of how we are devoted to the energy sector and will continue to bring in top talent to further help our clients achieve their goals. He has been a trusted advisor to senior executives and boards of directors, known for cultivating and sustaining relationships across decades and market cycles," said Spencer Rippstein, global co-head of energy, power & infrastructure investment banking at Piper Sandler. With over 28 years of investment banking e

    1/29/26 9:01:00 AM ET
    $PIPR
    Investment Bankers/Brokers/Service
    Finance

    $ABBV
    $AON
    $BBU
    $BBUC
    Financials

    Live finance-specific insights

    View All

    Duff & Phelps Utility and Infrastructure Fund Inc. Discloses Sources of Distribution – Section 19(a) Notice

    The Board of Directors of Duff & Phelps Utility and Infrastructure Fund Inc. (NYSE:DPG), a closed-end fund advised by Duff & Phelps Investment Management Co., previously announced the following monthly distribution on December 11, 2025: Per Share Amount Ex-Date Record Date Payable Date $0.07 January 30, 2026 January 30, 2026 February 10, 2026 The Fund adopted a managed distribution plan (the "Plan") in 2015. Under the Plan, the Fund will distribute all available investment income to its shareholders, consistent with the Fund's investment objective. If and when sufficient investment income is not available on a monthly basis, the Fund wi

    2/9/26 4:05:00 PM ET
    $DPG
    $VRTS
    Trusts Except Educational Religious and Charitable
    Finance
    Investment Managers

    Cboe Global Markets Reports Results for Fourth Quarter 2025 and Full Year

    Fourth Quarter and Full Year Highlights* Record Diluted EPS for the Quarter of $2.97, Up 60 percent; Record Diluted EPS for the Full Year of $10.42, Up 45 percentRecord Adjusted Diluted EPS1 for the Quarter of $3.06, Up 46 percent; Record Adjusted Diluted EPS1 for the Full Year of $10.67, Up 24 percentRecord Net Revenue for the Quarter of $671.1 million, Up 28 percent; Record Net Revenue for the Full Year of $2.4 billion, Up 17 percentEstablishing 2026 Organic Total Net Revenue Growth Target2 of 'mid single-digit' and Cboe Data Vantage3 Organic Net Revenue Growth Target2 of 'mid to high single-digit'Establishing 2026 Adjusted Operating Expense Guidance2 of $864 to $879 millionCHICAGO, Feb. 6

    2/6/26 7:30:00 AM ET
    $CBOE

    Virtus Investment Partners Announces Financial Results for Fourth Quarter 2025

    Earnings Per Share - Diluted of $5.17; Earnings Per Share - Diluted, as Adjusted, of $6.50 Total Sales of $5.3B; Net Flows of ($8.1B); Assets Under Management of $159.5B Virtus Investment Partners, Inc. (NYSE:VRTS) today reported financial results for the three months ended December 31, 2025. Financial Highlights (Unaudited) (in millions, except per share data or as noted)   Three Months Ended       Three Months Ended       12/31/2025   12/31/2024   Change   9/30/2025   Change U.S. GAAP Financial Measures                

    2/6/26 7:00:00 AM ET
    $VRTS
    Investment Managers
    Finance

    $ABBV
    $AON
    $BBU
    $BBUC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by WisdomTree Inc.

    SC 13G - WisdomTree, Inc. (0000880631) (Subject)

    11/21/24 5:28:49 PM ET
    $WT
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Mizuho Financial Group Inc. Sponosred ADR (Japan)

    SC 13G - MIZUHO FINANCIAL GROUP INC (0001335730) (Filed by)

    11/14/24 8:53:27 PM ET
    $MFG
    Major Banks
    Finance

    SEC Form SC 13G filed by Mizuho Financial Group Inc. Sponosred ADR (Japan)

    SC 13G - MIZUHO FINANCIAL GROUP INC (0001335730) (Filed by)

    11/14/24 8:40:26 PM ET
    $MFG
    Major Banks
    Finance

    $ABBV
    $AON
    $BBU
    $BBUC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Exxon Mobil Corporation on Jun 20

    Director Dreyfus Maria S. bought $2,000,386 worth of shares (18,310 units at $109.25), increasing direct ownership by 105% to 35,757 units (SEC Form 4) on June 20, 2024. This substantial insider purchase is a significant development for Exxon Mobil Corporation. As we delve into the recent insider activity at Exxon Mobil, we notice a few interesting patterns. Prior to Dreyfus Maria S.'s purchase, we observed that on January 4, 2024, Ubben Jeffrey W. granted 2,500 shares, which could signal confidence in the company. On the same day, Powell Dina H. claimed no ownership of stock but was granted 8,000 shares, indicating a new ownership stake. These events suggest a mix of adjustments in holding

    6/20/24 1:39:11 PM ET
    $XOM
    Integrated oil Companies
    Energy